Vyne Therapeutics Inc Cash Flow-to-Debt Ratio
Vyne Therapeutics Inc cash flow-to-debt ratio. Vyne Therapeutics Inc (VYNE) has a Cash Flow-to-Debt Ratio of -1.57x as of December 2025, meaning its operating cash flow of $-3.76 Million could theoretically repay -2% of its total liabilities ($2.40 Million) in one year. Check Vyne Therapeutics Inc (VYNE) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Vyne Therapeutics Inc (2015–2025)
Cash flow-to-debt ratio of Vyne Therapeutics Inc from 2015 to 2025. Historical debt coverage capacity for Vyne Therapeutics Inc across 11 annual periods. Check Vyne Therapeutics Inc (VYNE) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Vyne Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Vyne Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Vyne Therapeutics Inc. For the full cash flow conversion analysis, see VYNE cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -13.83x | $-33.12 Million | $2.40 Million | ▼ -503.3% |
| 2024 | -2.29x | $-33.97 Million | $14.82 Million | ▲ +19.0% |
| 2023 | -2.83x | $-25.34 Million | $8.95 Million | ▲ +7.3% |
| 2022 | -3.06x | $-29.20 Million | $9.56 Million | ▲ +0.2% |
| 2021 | -3.06x | $-56.37 Million | $18.41 Million | ▼ -25.6% |
| 2020 | -2.44x | $-137.08 Million | $56.25 Million | ▲ +60.1% |
| 2019 | -6.11x | $-65.10 Million | $10.66 Million | ▼ -10.6% |
| 2018 | -5.52x | $-52.73 Million | $9.55 Million | ▼ -2321.8% |
| 2017 | -0.23x | $-28.25 Million | $123.90 Million | ▼ -611.4% |
| 2016 | -0.03x | $-2.29 Million | $71.49 Million | ▲ +54.2% |
| 2015 | -0.07x | $-4.18 Million | $59.84 Million | — |